Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cognitive function in schizophrenic patients

G D Tollefson1

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285, USA.

The Journal of Clinical Psychiatry
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.

International journal of psychiatry in clinical practice·2014
Same author

The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.

Journal of clinical psychopharmacology·2002
Same author

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

The Journal of clinical psychiatry·2001
Same author

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

The Journal of clinical psychiatry·2001
Same author

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

The Journal of clinical psychiatry·2001
Same author

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.

Biological psychiatry·2001
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Cognitive impairment in schizophrenia, affecting attention and memory, is a key challenge. New atypical medications show promise for improving these deficits and aiding patient reintegration.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cognitive Science

Background:

  • Cognitive impairment is a common feature of schizophrenia, impacting attention, memory, and executive functions.
  • While some studies suggest progressive decline, these deficits often remain stable over time.
  • Schizophrenia involves brain abnormalities in cortical, temporal, and limbic systems.

Purpose of the Study:

  • To summarize the nature of cognitive deficits in schizophrenia.
  • To highlight the neurobiological underpinnings of these impairments.
  • To discuss the therapeutic potential of atypical agents for cognitive dysfunction.

Main Methods:

  • Review of imaging and biochemical studies.
  • Analysis of neurochemical assays.

Related Experiment Videos

  • Examination of clinical outcomes related to cognitive function.

    • Main Results:

    • Schizophrenia is associated with morphological, hemodynamic, and neurochemical abnormalities.
    • Serotonin, dopamine, and glutamate neurotransmitters are implicated in cognitive decline.
    • Cognitive deficits significantly hinder psychosocial functioning and societal reintegration.

    Conclusions:

    • Cognitive impairment is a critical target for schizophrenia treatment.
    • Atypical antipsychotic agents like clozapine and olanzapine show potential for improving cognitive deficits.
    • Addressing cognitive dysfunction is vital for enhancing patient outcomes and facilitating recovery.